ASX Announcements

ASX Announcements

Due to legal restrictions, only residents of Australia and New Zealand may access ASX announcements that contain information or materials relating to any capital raising.

Date Title  
10 September 2019 Analyst Call Presentation
10 September 2019 Analyst Call Details
10 September 2019 Grunenthal and MSB Enter Strategic Partnership for Back Pain
30 August 2019 Mesoblast Reports 2019 Full Year Results
30 August 2019 Mesoblast Reports on Annual Results
30 August 2019 Annual Financial Results Presentation
30 August 2019 Preliminary Final Report including Appendix 4E
27 August 2019 FDA Guidance on Clinical Pathway for LVAD Market Application
14 August 2019 Investigator-Initiated Trial Planned for Chronic GVHD
12 August 2019 Mesoblast Appoints Leading Pharma Industry Executive as CMO
31 July 2019 Appendix 4C - Quarterly, Strong Commercialization Revenues
25 July 2019 Circulation Research Highlights MSB Heart Failure Therapy
15 July 2019 Newsletter - Interview with GvHD Key Opinion Leader
12 July 2019 Change in substantial holding
11 July 2019 Appendix 3B
26 June 2019 Release of Shares from Voluntary Escrow
24 June 2019 FDA Grants Revascor Orphan Drug For End Stage CHF With LVADs
18 June 2019 High Economic Burden In Steroid-Refractory aGVHD
17 June 2019 MSB to Host Virtual Symposium with KOL on GvHD
11 June 2019 MSB Expands JCR Partnership To Brain Disease In Newborns
31 May 2019 Mesoblast Reports Financial Results and Operational Highlights for the Period Ended March 31, 2019
31 May 2019 MSB Provides Q3 Financial Results and Operational Highlights
31 May 2019 Third Quarter Results Presentation
31 May 2019 Third Quarter Financial Results on Form 6-K
30 May 2019 MSB Financial Results Webcast Timing
30 May 2019 Mesoblast Initiates Rolling Submission of BLA for GvHD
23 May 2019 Mesoblast Keynote Presentations at ISCT Annual Meeting
17 May 2019 Mesoblast to Present at RBC Global Healthcare Conference
30 April 2019 Appendix 4C - quarterly
16 April 2019 FDA Agrees to Rolling Review of Mesoblast BLA Submission
05 April 2019 Final Director's Interest Notice
05 April 2019 Presentation at Upcoming Global Life Science Conference
27 March 2019 MoU for Confirmatory Trial for GI Bleeding in LVAD Patients
25 March 2019 MSB Licensee Files For Skin Disease Marketing Approval
22 March 2019 Joseph R. Swedish Appointed Mesoblast Chairman
18 March 2019 Change in substantial holding
13 March 2019 Upcoming U.S. Investor Conferences
20 February 2019 Mesoblast Reports Financial Results and Operational Highlights for the First Half Ended December 31, 2018
21 February 2019 Mesoblast Provides Half Year Results and Corporate Update
21 February 2019 Half Year Financial Results Presentation
21 February 2019 Half Year Report and Accounts (including Appendix 4D)
19 February 2019 Final Patient Dosed in Mesoblast P3 Heart Failure Trial
19 February 2019 Mesoblast Newsletter on Advanced and End-Stage Heart Failure
11 February 2019 Change in substantial holding
31 January 2019 Appendix 4C - quarterly
14 January 2019 MSB Draws US$15 Million From Existing Facility
08 January 2019 MSB Highlights Key 2019 Priorities at U.S. Biotech Showcase
08 January 2019 Change of Director's Interest Notices
07 January 2019 P3 Trial of MSB's Cell Therapy in CHF Completes Recruitment
07 January 2019 Cleansing notice and Appendix 3B

Share Price :    as of Sep 07, 2019